Archives
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
- 2021-12
- 2021-11
- 2021-10
- 2021-09
- 2021-08
- 2021-07
- 2021-06
- 2021-05
- 2021-04
- 2021-03
- 2021-02
- 2021-01
- 2020-12
- 2020-11
- 2020-10
- 2020-09
- 2020-08
- 2020-07
- 2020-06
- 2020-05
- 2020-04
- 2020-03
- 2020-02
- 2020-01
- 2019-12
- 2019-11
- 2019-10
- 2019-09
- 2019-08
- 2019-07
- 2019-06
- 2019-05
- 2019-04
- 2018-11
- 2018-10
- 2018-07
-
Heat shock protein Hsp is a molecular chaperone that plays
2024-02-20

Heat shock protein 90 (Hsp90) is a molecular chaperone that plays a central role in regulating the maturation, activation and stability of numerous “client proteins” that drive the development and progression of many cancers. Therefore, inhibition of Hsp90 would result in degradation of the client p
-
br Materials and methods br
2024-02-20

Materials and methods Results Discussion In the present study, we identified HBP1 as a novel substrate of AKT. This was demonstrated by in vitro phosphorylation assays and western blotting using phosphosite-specific antibodies. Three sites were identified by mass spectrometry and mutagenesi
-
THZ2 It is important to note that stable amnesia is
2024-02-20

It is important to note that stable amnesia is, apparently, a general biological phenomenon and can be found in different animal species. In studies on rats, it was found that if reconsolidation of conditioned olfactory aversion memory was impaired by the antagonist of NMDA glutamate receptors, amne
-
br Conflict of interest br
2024-02-20

Conflict of interest Acknowledgements The authors would like to thank Mrs. Amparo Pacheco from CMPL, PUC, for her technical and secretarial assistance. This work was supported by the Fondo Nacional de Desarrollo Científico y Tecnológico (FONDECYT 1150344, 1050377, 11150083), and the Direccioń
-
Our analysis demonstrated that ADA is
2024-02-20

Our analysis demonstrated that ADA is a transpicuous and rapid test with high sensitivity and specificity for diagnosis of TBM decidedly. The summary sensitivity and specificity were 0.89 and 0.91 respectively, indicating a sufficient level for overall diagnostic accuracy. The modality of SROC curve
-
In addition we performed Western blot analysis of different
2024-02-20

In addition, we performed Western-blot analysis of different areas of mouse brain with LJH685 against mAck1 (Ureña et al., 2005). The data obtained showed a high rate of expression in neocortex, hippocampus, cerebellum, and brainstem (Fig. 4). More moderate levels of expression were seen in hypotha
-
HT receptors are distributed throughout the brain within
2024-02-20

5-HT3 receptors are distributed throughout the brain, within the brainstem (e.g., nucleus tractus solitarius, area postrema and spinal trigeminal nucleus) and omadacycline (e.g., hippocampus, amygdala, nucleus accumbens, putamen and caudate) (Abi-Dargham et al., 1993, Barnes et al., 1989, Bufton et
-
In conclusion AXL overexpression preexisted in a subgroup of
2024-02-20

In conclusion, AXL overexpression preexisted in a subgroup of treatment-naive lung adenocarcinoma specimens harboring an activating EGFR mutation or in those with wild-type EGFR. Anti-AXL therapeutics delivered up front in combination with the EGFR inhibitor might overcome intrinsic or acquired resi
-
Small kinase inhibitors have been
2024-02-20

Small kinase inhibitors have been developed to block AXL by interacting with the kinase cytoplasmic ATP binding site. Up to date, no AXL selective kinase inhibitors are marketed. As depicted in , some marketed kinase inhibitors such as Bosutinib and Cabozantinib or kinase inhibitors in clinical pha
-
E-64 br Conflicts of interest br Introduction Phosphatidic a
2024-02-20

Conflicts of interest Introduction Phosphatidic E-64 phosphatase (PAP) enzymes are responsible for catalyzing the reaction that dephosphorylates phosphatidic acid (PA), which in turn produces diacylglycerol (DAG) and a phosphate group during phospholipid regulation (Fig. 1A) [1]. Subsequently
-
As aforementioned this study aimed to design synthesize and
2024-02-20

As aforementioned, this study aimed to design, synthesize and investigate aromatase inhibitory and anti-breast cancer activities of N,N′-disubstituted thiourea derivatives. Based on the attractive phenotypic molecule 1, the synthetic N,N′-disubstituted thioureas have been designed including monothio
-
br Conclusion We present here the
2024-02-20

Conclusion We present here the first comprehensive analysis of B-Raf-induced transcriptional activation in insulinoma cells. The B-Raf-induced signaling cascade targets the c-Fos and the c-Jun genes. Both gene products are constituents of the AP-1 transcription factor. The phosphatases MKP-1 and
-
In a missense mutation at codon of the PRNP
2024-02-20

In 1989, a missense mutation at codon 102 of the PRNP gene was first reported to be associated with GSS and, in 1991, the same mutation was also found in affected members of the “H” family (Hsiao et al., 1989; Kretzschmar et al., 1991). By 1995, the pedigree of the “H” family included 221 family mem
-
The reasons why antibiotic treatment
2024-02-20

The reasons why antibiotic treatment may be detrimental are diverse. First, it may result in disruption of multifaceted microbe–microbe, as well as microbe–host, interactions that are key for the maintenance of homeostasis within this ecosystem. This can lead to the expansion of pathogenic microorga
-
The major phase trial NCT enrolled participants with
2024-02-19

The major phase 2 trial (NCT01343966) enrolled 431 participants with mild to moderate AD who received either low-dose SC crenezumab 300 mg or placebo biweekly (n = 184) or high-dose intravenous crenezumab 15 mg/kg or placebo every 4 weeks (n = 247) for 68 weeks 38, 40. No significant treatment benef
15757 records 194/1051 page Previous Next First page 上5页 191192193194195 下5页 Last page